In a recent update that has the medical community paying attention, a new study known as the COBRA trial is shaking things up in the treatment of multiple myeloma. During the American Society of Hematology (ASH) 2025 Annual Meeting, research led by Dominik Dytfeld, MD, from Poland, presented findings that show patients experiencing a substantial improvement when treated with a combination of carfilzomib, lenalidomide, and dexamethasone (KRd). The alternative regimen consists of lenalidomide and dexamethasone plus bortezomib (VRd), but in comparison, KRd led to a 43% greater reduction in the risk of death or disease progression after a median observation of 53 months, as noted by the University of Cincinnati Cancer Center.
Ed Faber, DO, who is not only an author of the preceding ENDURANCE trial but also an associate professor at UC's College of Medicine and a director at the University's Cancer Center, elucidated the finer points of the study during his commentary to Medscape Faber explained the complex relationship between efficacy and toxicity profiles associated with these regimens, while highlighting the importance of balancing the two to optimize patient outcomes in a context where nuanced treatment adjustments have a significant impact.
Delving into the specifics, Faber mentioned, "What we learned from ENDURANCE is that complete response and very good partial response favored KRd versus VRd, however, the toxicity profile abrogated this benefit, thus [progression free survival] and [overall survival] were similar," which was noted in his commentary to Medscape, according to UC News. In the current COBRA study, it seems the trend continues with KRd having a higher rate of grade 3 adverse effects than VRd, along with increased cardiac side effects.
However, despite the enhanced risk of neuropathy, which is a side effect well-known to those familiar with VRd, the positive response rate observed with KRd remains noteworthy and highlights an ongoing challenge for clinicians to strike the right balance between treatment effectiveness and the management of side effects simply put, this data adds another layer of complexity to an already intricate decision-making process for the treatment of multiple myeloma, showcasing the ongoing evolution in the field of hematologic oncology.
